Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
AssigneesThe Regents of the University of California, Universidad Autonoma de Nuevo Leon
InventorsAlbert ZLOTNIK, Peter HEVEZI, Van LUU, Juan Pablo FLORES
Life of this patent
Estimating the term…
Abstract
A method of treating a disease associated with activated B lymphocytes expressing Tetraspanin 33 (TSPAN33/BAAM). The disease can be, for example, lymphoma or an immune disease. The method includes administering an anti-TSPAN33/BAAM antibody to a patient in need of such treatment in an amount effective to treat the disease. Methods of purifying activated B cells and identifying activated and/or diseased B cells are also provided.
Claims20
A method of treating a lymphoma or leukemia in which TSPAN33 is upregulated, comprising administering an anti-TSPAN33 antibody to a patient in need of such treatment in an amount effective to treat the lymphoma or leukemia.
A method of treating an immune disease in which TSPAN33 is upregulated, comprising administering an anti-TSPAN33 antibody to a patient in need of such treatment in an amount effective to treat the immune disease.
A method of purifying activated B-lymphocytes, comprising mixing an anti-TSPAN33 antibody with a lymphocyte-containing cell preparation, and separating lymphocytes bound by the antibody.
A method of identifying an activated and/or diseased B-lymphocyte, comprising detecting upregulated expression of TSPAN33 in the lymphocyte.
Dependencies are inferred from the claim text.